Windtree Therapeutics Initiates SEISMiC C Study Of Istaroxime In SCAI Stage C Cardiogenic Shock For Planned Completion Of Phase 2b And Transition To Phase 3
Portfolio Pulse from Benzinga Newsdesk
Windtree Therapeutics has initiated the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock, aiming to complete Phase 2b and transition to Phase 3. The study follows successful SEISMiC A and B trials, with plans to engage regulatory authorities in 2025.
October 30, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Windtree Therapeutics has begun the SEISMiC C study for istaroxime in severe cardiogenic shock, following positive results in earlier trials. The company plans to transition to Phase 3 in 2025.
The initiation of the SEISMiC C study represents a significant step forward for Windtree Therapeutics, as it follows successful earlier trials and aims for a Phase 3 transition. This progress is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100